ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of “Buy” by Analysts

Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) have been given a consensus recommendation of “Buy” by the six analysts that are covering the stock, MarketBeat reports. Four research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $24.00.

A number of research analysts have recently commented on SPRY shares. Leerink Partners lifted their price objective on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an “outperform” rating in a research report on Friday, September 20th. Cantor Fitzgerald reissued an “overweight” rating and issued a $30.00 price objective on shares of ARS Pharmaceuticals in a research report on Tuesday, October 8th. William Blair raised shares of ARS Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. Finally, Raymond James raised shares of ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and lifted their price objective for the company from $18.00 to $22.00 in a research report on Tuesday, August 13th.

Insider Transactions at ARS Pharmaceuticals

In other news, insider Sarina Tanimoto sold 100,000 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $14.88, for a total transaction of $1,488,000.00. Following the completion of the sale, the insider now owns 1,298,499 shares in the company, valued at approximately $19,321,665.12. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other ARS Pharmaceuticals news, Director Peter A. Thompson sold 407,700 shares of ARS Pharmaceuticals stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $13.56, for a total value of $5,528,412.00. Following the completion of the sale, the director now owns 544,677 shares in the company, valued at $7,385,820.12. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $14.88, for a total transaction of $1,488,000.00. Following the completion of the sale, the insider now owns 1,298,499 shares of the company’s stock, valued at $19,321,665.12. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,055,895 shares of company stock worth $14,619,032. 40.10% of the stock is owned by insiders.

Hedge Funds Weigh In On ARS Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. US Bancorp DE raised its position in shares of ARS Pharmaceuticals by 11,951.6% in the 3rd quarter. US Bancorp DE now owns 18,680 shares of the company’s stock valued at $271,000 after buying an additional 18,525 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of ARS Pharmaceuticals by 63.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 18,645 shares of the company’s stock valued at $270,000 after purchasing an additional 7,262 shares during the last quarter. J.W. Cole Advisors Inc. boosted its stake in shares of ARS Pharmaceuticals by 33.2% in the 3rd quarter. J.W. Cole Advisors Inc. now owns 20,520 shares of the company’s stock valued at $298,000 after purchasing an additional 5,120 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in shares of ARS Pharmaceuticals by 9.1% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 57,624 shares of the company’s stock valued at $836,000 after purchasing an additional 4,810 shares during the last quarter. Finally, TFG Advisers LLC bought a new stake in shares of ARS Pharmaceuticals in the 3rd quarter valued at $180,000. 68.16% of the stock is currently owned by institutional investors and hedge funds.

ARS Pharmaceuticals Trading Up 3.7 %

ARS Pharmaceuticals stock opened at $15.26 on Friday. The company has a market cap of $1.48 billion, a P/E ratio of -32.47 and a beta of 0.90. ARS Pharmaceuticals has a 1-year low of $3.38 and a 1-year high of $17.08. The company has a fifty day simple moving average of $14.05 and a 200 day simple moving average of $11.22.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The firm had revenue of $0.50 million for the quarter, compared to the consensus estimate of $2.00 million. On average, equities research analysts forecast that ARS Pharmaceuticals will post -0.66 EPS for the current year.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.